Article Text

PDF
SAT0158 Efficacy of switching from etanercept to adalimumab in rheumatoid arthritis and psoriatic arthritis patients who experienced a first-line biologic therapy failure: the fearless study
  1. EG Favalli1,
  2. A Becciolini1,
  3. A Carletto2,
  4. F Conti3,
  5. G Amato4,
  6. E Fusaro5,
  7. L Quartuccio6,
  8. A Lo Monaco7,
  9. M Benucci8,
  10. F Salaffi9,
  11. A Semeraro10,
  12. M Biggioggero11,
  13. S Parisi5,
  14. F Ceccarelli3,
  15. I Piazza2,
  16. R Foti4
  1. 1Department of Rheumatology, Gaetano Pini Institute, Milano
  2. 2Rheumatology Unit, AOUI, Verona
  3. 3Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, Roma
  4. 4Rheumatology Unit, A.O.U. Policlinico Vittorio Emanuele, Catania
  5. 5Rheumatology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Torino
  6. 6Clinica di reumatologia, Dipartimento di scienze mediche e biologiche, ASUIUD, Udine
  7. 7UOC di Reumatologia, Azienda Ospedaliero-Universitaria Sant'Anna Cona-Ferrara, Ferrara
  8. 8SOS Reumatologia, Ospedale S. Giovanni di Dio, Firenze
  9. 9Clinica Reumatologica, Università Politecnica delle Marche, Ancona
  10. 10U.O.Reumatologia, ASL Taranto-PP.OO.SS. Annunziata Taranto e Valle d'Itria, Taranto
  11. 11Department of Clinical Sciences and Community Health, Division of Rheumatology, University of Milan and Gaetano Pini Institute, Milano, Italy

Abstract

Background The strategy for the choice of the second biologic agent after the failure of the first TNF inhibitor (TNFi) is still an unclear aspect in the treatment of both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Switching between structurally different TNFis (from etanercept [ETN] to monoclonal antibody [mAb] or vice versa) has been proposed as a more effective procedure than switching among different mAbs, but to date no study has been specifically focused on exploring this topic.

Objectives To evaluate the comparative 2-year retention rate and the 12-month efficacy of adalimumab (ADA) as second biologic agent in etanercept (ETN) non-responder RA and PsA patients in a multicentre retrospective study.

Methods All RA and PsA patients from 11 Italian Rheumatology Units treated with ADA after a first-course ETN failure and with at least 12-month follow-up were retrospectively collected in a multicentre registry. Data analysis was limited to the period from January 2002 to May 2016. Two-year ADA retention rate was calculated by Kaplan-Meier method. 12-month ADA response was defined as achievement of disease activity score 28 calculated by using erythrosedimentation (DAS28-ESR) <2.6 (remission) or >2.6 and <3.2 (low disease activity, LDA). Sub-analyses according to reason for ETN discontinuation and concomitant methotrexate in RA and PsA patients have been performed.

Results The study population (219 patients) included 117 RA (female 85.5%, mean [± standard deviation, SD] age 53.2±13.5 years, mean [±SD] disease duration 10.1±7.7; positive rheumatoid factor 70.2%; positive anti-citrullinated peptide antibodies [ACPA] 59.6%; mean [±SD] baseline DAS28-ESR 4.97±1.3; MTX users 64.9%) and 102 PsA (female 63.7%; mean [±SD] age 51.7±10.6; mean [±SD] disease duration 7.1±5.1; mean [±SD] baseline DAS28-ESR 4.4±1.1; MTX users 50%). The 2-year retention rate was 48.2% in RA and 56.5% in PsA patients, irrespective of reason for ETN discontinuation. Similarly, concomitant MTX was not associated with an increased drug survival in both RA (p=0.09) and PsA (p=0.969) subgroup. 12-month clinical remission and LDA were achieved respectively in 27.3% and 23.9% RA patients, and 27.4% and 23.5% PsA patients.

Conclusions In our large real-life cohort, the use of ADA in primary and secondary ETN failures was highly effective in both RA and PsA patients, with more than 50% of ADA treated patients achieving remission or LDA. Reasons for ETN discontinuation were not associated with different ADA clinical response, as well as concomitant MTX.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.